Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics director reports planned stock sales
Luke Evnin, a director of Werewolf Therapeutics, Inc. (HOWL), reported three sales of common stock made under a Rule 10b5-1 trading plan dated September 24, 2025. On November 21, 2025, affiliated investment entities sold a total of 41,287 shares at a weighted average price of $0.83 per share. On November 24, 2025, they sold 56,992 shares at a weighted average price of $0.98 per share, and on November 25, 2025, they sold 27,297 shares at a weighted average price of $0.92 per share.
After these transactions, entities associated with Evnin beneficially owned a total of 3,287,551 HOWL shares across several MPM-managed funds and vehicles. The filing states that Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by entities affiliated with MPM BioImpact, which is identified as a director and 10% owner group. On 11/21/2025, these affiliated funds sold 64,331 shares of common stock at a weighted average price of $0.83. On 11/24/2025, they sold another 88,802 shares at a weighted average price of $0.98, and on 11/25/2025 they sold 42,533 shares at a weighted average price of $0.92. The filing states that these trades were made under a Rule 10b5-1 trading plan dated September 24, 2025. After these transactions, the reporting group collectively held 5,125,770 shares of Werewolf Therapeutics common stock through various affiliated investment vehicles.
Werewolf Therapeutics, Inc. (HOWL) insider filing shows planned share sales by MPM-affiliated funds. A reporting group connected to MPM BioImpact and related investment vehicles sold 64,331 shares of common stock on 11/21/2025 at a weighted average price of $0.83, 88,802 shares on 11/24/2025 at $0.98, and 42,533 shares on 11/25/2025 at $0.92.
The sales were executed under a Rule 10b5-1 trading plan dated September 24, 2025, which is designed to pre-arrange trades. After these transactions, the reporting persons collectively report indirect beneficial ownership of 5,125,770 HOWL shares through several affiliated funds.
Werewolf Therapeutics director Luke Evnin reported a series of open-market sales of the company’s common stock under a pre-established Rule 10b5-1 trading plan dated September 24, 2025. On November 18, 2025, affiliated funds sold 33,776 shares at a weighted average price of $0.93, leaving 3,482,104 shares beneficially owned indirectly. On November 19, 2025, they sold 42,566 shares at a weighted average price of $0.94, leaving 3,439,538 shares. On November 20, 2025, they sold 26,411 shares at a weighted average price of $0.89, leaving 3,413,127 shares. The filing explains that the shares are held through various MPM-affiliated entities and that Evnin disclaims beneficial ownership beyond his pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL) reported insider activity by MPM-affiliated entities on a Form 4. Investment vehicles associated with MPM BioImpact and related funds, which are reported as a director and 10% owner group, sold Werewolf Therapeutics common stock on three days under a pre-arranged Rule 10b5-1 trading plan dated September 24, 2025.
The group sold 52,627 shares on November 18, 2025 at a weighted average price of $0.93, 66,324 shares on November 19, 2025 at a weighted average price of $0.94, and 41,152 shares on November 20, 2025 at a weighted average price of $0.89. After these sales, they reported indirect beneficial ownership of 5,321,436 shares held across several MPM-managed entities, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund and UBS Oncology Impact Fund, with each reporting person disclaiming beneficial ownership beyond its pecuniary interest.
Werewolf Therapeutics, Inc. (HOWL) reported insider transactions by entities affiliated with MPM BioImpact LLC, which is identified as a director and 10% owner. Over three days, from 11/18/2025 to 11/20/2025, these reporting persons sold a total of 160,103 shares of common stock in open-market transactions. The weighted average sale prices were around $0.93 on 11/18, $0.94 on 11/19, and $0.89 on 11/20, with detailed price ranges provided for each day. After these sales, the reporting group continued to beneficially own 5,321,436 shares of Werewolf Therapeutics indirectly through multiple affiliated investment vehicles. The filing notes that the trades were executed under a Rule 10b5-1 trading plan dated September 24, 2025.
Werewolf Therapeutics (HOWL) director Luke Evnin reported a series of planned insider stock sales under a Rule 10b5-1 trading plan. On 11/13/2025, affiliated MPM entities sold 58,372 shares of common stock at a weighted average price of $0.98. On 11/14/2025, they sold 39,560 shares at a weighted average price of $0.93, and on 11/17/2025, they sold 36,621 shares at a weighted average price of $0.95. After these transactions, Evnin reported 3,515,880 shares of HOWL common stock beneficially owned indirectly through various MPM investment vehicles. The filing notes that prices are reported as weighted averages for multiple trades within specified price ranges.
Werewolf Therapeutics, Inc. (HOWL) reported insider stock sales by an affiliated director and 10% owner. Investment entities associated with MPM BioImpact LLC filed a Form 4 showing automatic sales of common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On November 13, 2025, they sold 90,951 shares at a weighted average price of $0.98 per share, followed by 61,640 shares at $0.93 on November 14 and 57,061 shares at $0.95 on November 17. After these transactions, the group reported indirect beneficial ownership of 5,481,539 shares held across several MPM-managed funds, while disclaiming beneficial ownership beyond their economic interest. This filing is one of two identical submissions due to limits on the number of reporting persons.
Werewolf Therapeutics, Inc. (HOWL) director and 10% owner affiliated with MPM BioImpact reported planned insider stock sales. The filing covers three open‑market sales of Werewolf common stock executed under a Rule 10b5-1 trading plan dated September 24, 2025.
On November 13, 2025, the reporting group sold 90,951 shares at a weighted average price of $0.98. On November 14, 2025, they sold 61,640 shares at a weighted average price of $0.93, and on November 17, 2025, they sold 57,061 shares at a weighted average price of $0.95. Each day’s trades occurred across multiple prices within disclosed ranges.
After these transactions, the group reports indirect beneficial ownership of 5,481,539 Werewolf shares held through several affiliated investment vehicles, including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Oncology Innovations Fund, and UBS Oncology Impact Fund.
Werewolf Therapeutics (HOWL) — Form 4 insider activity: Director Luke Evnin reported open‑market sales of company common stock executed under a Rule 10b5‑1 trading plan dated September 24, 2025. Sales occurred on four dates: 11/07/2025 (43,950 shares at a weighted average price of $1.11), 11/10/2025 (31,172 at $1.18), 11/11/2025 (35,818 at $1.14), and 11/12/2025 (26,101 at $1.09).
Following these transactions, the reported indirect beneficial holdings were updated to 3,743,524; 3,712,352; 3,676,534; and 3,650,433 shares, respectively. The holdings are indirect through affiliated entities (including AM LLC, BV 2014, BV 2014(B), AM BV2014, and MPM OIF), with a stated disclaimer of beneficial ownership beyond pecuniary interest.